Abstract
Eradication of H. pylori is generally achieved by the administration of antibiotics under acid inhibition. The clinical efficacy of proton pump inhibitors, which inhibit gastric acid secretion, differs depending on the activity of metabolizing enzymes. Thus, drugs which are rapidly metabolized will have a decreased therapeutic effect and may require increased doses. Antibiotic resistance of H. pylori is also critical, and antibiotic drugs must be selected according to antibiotic resistance. Furthermore, antibiotics have their own characteristics, and some need to be administrated three or four times a day rather than uniformly twice a day. Standard therapy might not be indicated for certain patients, such as those with penicillin allergy and/or deterioration of renal function and receiving dialysis for renal failure. Accordingly, it may be necessary to provide personalized therapy based on the characteristics of each case.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Sachs G, et al. Acid, protons and Helicobacter pylori. Yale J Biol Med. 1996;69(3):301–16.
Furuta T, Graham DY. Pharmacologic aspects of eradication therapy for Helicobacter pylori infection. Gastroenterol Clin North Am. 2010;39(3):465–80.
Furuta T, Sugimoto M, Shirai N. Individualized therapy for gastroesophageal reflux disease: Potential impact of pharmacogenetic testing based on CYP2C19. Mol Diagn Ther. 2012;16(4):223–34.
Furuta T, et al. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther. 1999;65(5):552–61.
Furuta T, et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med. 1998;129(12):1027–30.
Furuta T, et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther. 2001;69(3):158–68.
Furuta T, et al. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther. 2007;81(4):521–8.
Sasaki M, et al, Changes in 12-year first-line eradication rate of Helicobacter pylori based on triple therapy with proton pump inhibitor, amoxicillin and clarithromycin. J Clin Biochem Nutr. 47(1):pp. 53–8.
Shirai N, et al. Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy. Eur J Clin Pharmacol. 2007;63(8):743–9.
Furuta T, et al. Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H. pylori infection. Clin Gastroenterol Hepatol. 2005;3(6):564–73.
Nishizawa T, et al. Gatifloxacin resistance and mutations in gyra after unsuccessful Helicobacter pylori eradication in Japan. Antimicrob Agents Chemother. 2006;50(4):1538–40.
Hassan IJ, et al. Absence of a post-antibiotic effect (PAE) of beta-lactams against Helicobacter pylori NCTC 11637. J Antimicrob Chemother. 1998;42(5):661–3.
Furuta T, et al. The dual therapy with 4 times daily dosing of rabeprazole and amoxicillin as the 3rd rescue regimen for eradication of H. pylori. Hepatogastroenterology. 2010;57(102–103):1314–9.
Miehlke S, et al. A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter. 2003;8(4):310–9.
Furuta T, et al. Effect of dosing schemes of amoxicillin on eradication rates of Helicobacter pylori with amoxicillin-based triple therapy. J Clin Pharmacol. 2014;54(3):258–66.
Furuta T, et al. Personalized therapy for H. pylori infection based on automated SNP analysis. Gastroenterology. 2014;146(5 Suppl 1):104.
Furuta T, et al. Eradication of H. pylori infection in patients allergic to penicillin using triple therapy with a PPI, metronidazole and sitafloxacin. Intern Med. 2014;53(6):571–5.
Sheu BS, et al. The selection of triple therapy for Helicobacter pylori eradication in chronic renal insufficiency. Aliment Pharmacol Ther. 2003;17(10):1283–90.
Araki H, et al. Significance of serum pepsinogens and their relationship to Helicobacter pylori infection and histological gastritis in dialysis patients. Nephrol Dial Transplant. 1999;14(11):2669–75.
Tokushima H, et al. Eradication of Helicobacter pylori in patients with end-stage renal disease undergoing dialysis treatment. Nihon Jinzo Gakkai Shi. 1996;38(8):349–55.
Chang WC, et al. Helicobacter pylori eradication with a 7-day low-dose triple therapy in hemodialysis patients. Clin Exp Nephrol. 2010;14(5):469–73.
Furuta T, et al. Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan. J Gastroenterol Hepatol. 2014;29(3):487–93.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Japan
About this chapter
Cite this chapter
Furuta, T. et al. (2016). Personalized Therapy in H. pylori Eradication. In: Suzuki, H., Warren, R., Marshall, B. (eds) Helicobacter pylori. Springer, Tokyo. https://doi.org/10.1007/978-4-431-55705-0_14
Download citation
DOI: https://doi.org/10.1007/978-4-431-55705-0_14
Published:
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-55704-3
Online ISBN: 978-4-431-55705-0
eBook Packages: MedicineMedicine (R0)